OTCMKTS:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis $12.95 -0.05 (-0.38%) As of 10:33 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsShort Interest About LogicBio Therapeutics Stock (OTCMKTS:LOGC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$12.95▼$13.0050-Day Range$13.00▼$15.4652-Week Range$7.05▼$15.60Volume5,027 shsAverage Volume136,169 shsMarket Capitalization$592.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease. The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery. Alexion Pharmaceuticals, part of AstraZeneca, completed its acquisition of LogicBio in 2022. LogicBio’s programs and platforms therefore became part of Alexion’s rare-disease research activities.AI Generated. May Contain Errors. Read More LogicBio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreLOGC MarketRank™: 0.487137383685 of 5 starsLogicBio Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.15% of the float of LogicBio Therapeutics has been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in LogicBio Therapeutics has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. News and Social Media1.5 / 5News SentimentN/A News SentimentLogicBio Therapeutics has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for LogicBio Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LOGC Stock News HeadlinesContextLogic Holdings Inc. Publishes Q&A Following Third Quarter 2026 ResultsNovember 18 at 4:05 PM | globenewswire.comLogicBio Therapeutics (OTCMKTS:LOGC) Shares Gap Down on Disappointing EarningsNovember 12, 2026 | americanbankingnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 19 at 1:00 AM | Decentralized Masters (Ad)LogicBio Therapeutics (OTCMKTS:LOGC) Share Price Breaks Below 50 Day Moving Average on Disappointing EarningsNovember 11, 2026 | americanbankingnews.comContextLogic Holdings Inc. Reports Third-Quarter 2026 Financial ResultsNovember 9, 2026 | globenewswire.comContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 ResultsAugust 21, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comContextLogic to Acquire gChem for $850 MillionAugust 5, 2026 | globenewswire.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How have LOGC shares performed this year? LogicBio Therapeutics' stock was trading at $7.58 at the beginning of 2026. Since then, LOGC shares have increased by 71.5% and is now trading at $13.00. How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) released its quarterly earnings results on Monday, November, 9th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.25. The business had revenue of $32.20 million for the quarter, compared to the consensus estimate of $32.20 million. How do I buy shares of LogicBio Therapeutics? Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Editas Medicine (EDIT), Precision BioSciences (DTIL), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), HOOKIPA Pharma (HOOK) and Cabaletta Bio (CABA). Company Calendar Last Earnings11/09/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:LOGC CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year Founded2014Profitability EPS (Trailing Twelve Months)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29 million Net MarginsN/A Pretax Margin-79.53% Return on Equity-2.86% Return on Assets-2.14% Debt Debt-to-Equity Ratio0.29 Current Ratio1.43 Quick Ratio0.94 Sales & Book Value Annual Sales$10.16 million Price / Sales58.28 Cash FlowN/A Price / Cash FlowN/A Book Value$15.80 per share Price / Book0.82Miscellaneous Outstanding Shares45,731,000Free Float26,309,000Market Cap$592.22 million OptionableNo Data Beta2.11 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:LOGC) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.